ctDNA shapes anti-EGFR rechallenge strategies in metastatic colorectal cancer
Recent research shows that molecular monitoring is key to identify a patient-tailored window of opportunity for rechallenge
Zanzalintinib plus atezolizumab shows activity in metastatic colorectal cancer with microsatellite stable disease
Primary phase III overall survival analysis suggests that the combination therapy may be a potential new option for previously treated patients with or without liver metastases
Novel immunotherapy combinations address unmet needs in liver cancers
Potentially practice-changing data were presented for atezolizumab plus bevacizumab, and camrelizumab plus rivoceranib in hepatocellular carcinoma
Disitamab vedotin plus immunotherapy almost doubles overall survival in advanced HER2 expressing urothelial cancer
The combination, incorporating the novel antibody–drug conjugate, may transform first-line treatment in the setting, but crucial issues need to be addressed
Triple combination with radioligand therapy improves radiographic progression-free survival in metastatic prostate cancer
Presidential Symposium presentation provides insights into the role of 177Lu-PSMA-617 in the treatment of hormone-sensitive prostate cancer, with results also presented in castration-resistant disease
Sacituzumab tirumotecan offers a promising new option for pre-treated EGFR-mutated non-small cell lung cancer
Phase III data show significant survival improvements with the TROP2-directed antibody–drug conjugate after progression on EGFR tyrosine kinase inhibitors
Immunotherapy combinations enhance radiotherapy response in resectable sarcoma
Effective biomarkers and histology-focused enrichment trials are now needed to further improve patient outcomes
Novel treatment strategies investigated for thymic epithelial tumours lead to uncertain benefits
Rivoceranib after prior therapy and peri-operative pembrolizumab demonstrates promising efficacy but it is not superior to the current standard therapy
First-line ivonescimab plus chemotherapy improves progression-free survival in squamous NSCLC
Robust efficacy findings and unexpectedly low haemorrhagic events were observed with the bispecific antibody but results will only change practice if benefits translate into overall survival and are replicated beyond China
Dose-dense paclitaxel and novel combination maintenance therapies offer survival benefits in advanced ovarian cancer
Positive results are reported from the FZOCUS-1 and ICON8B studies